Glycopeptides: Update on an old successful antibiotic class

Biochemical Pharmacology

Volumn 71, Issue 7, 2006, Pages 968-980

  Pace, John L ^a   Yang, Guang ^b  

^a Protez Pharmaceuticals   (United States)

^b Laviana Corporation   (United States)

Author keywords

Antibiotic; Delbavancin; Glycopeptide; Mechanism; Resistance; Telavancin

Indexed keywords

A 40926; AC 986446; ANTIBIOTIC AGENT; AVOPARCIN; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CEPHELEXIN; CHLORAMPHENICOL; CHLOREREMOMYCIN; CHLOROORIENTICIN A; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; ORITAVANCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; TEICOPLANIN; TELAVANCIN; THRX 1179; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 33644521754     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.12.005     Document Type: Article

References (182)

1. R. Nagarajan Glycopeptide antibiotics 1994 Marcel Dekker New York
2. J.L. Pace, R. Verna, and J. Verhoef Glycopeptide antibacterials and the treatment of biofilm related infections J.L. Pace M.E. Rupp R.G. Finch Biofilms, infection, and antimicrobial therapy 2005 CRC Press Boca Raton 385 400
3. R.G. Finch, and G.M. Eliopoulos Safety and efficacy of glycopeptide antibiotics J Antimicrob Chemother 55 2005 S5 S13
4. H.A. Kirst, D.G. Thompson, and T.I. Nicas Historical yearly usage of vancomycin Antimicrob Agents Chemother 42 1998 1303 1304
5. V.G. Fowler Jr. Current and future antibiotics for treatment of resistant Gram-positive infections Clin Updates Infect Dis 7 2004 1 4
6. H.F. Chambers Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications Microbiol Rev 10 1997 781 791
7. H.F. Chambers Community-associated MRSA-resistance and virulence converge N Engl J Med 352 2005 1485 1487
8. S.V. Karzakova, J.C. Hageman, M. Matava, A. Srinivasan, L. Phelan, and B. Garfinkel A clone of methicillin-resistant Staphylococcus aureus among professional football players N Engl J Med 352 2005 468 475
9. S.K. Fridkin, J.C. Hageman, M. Morrison, L.T. Sanza, K. Como-Sabetti, and J.A. Jernigan Active bacterial core surveillance program of the emerging infections program network, methicillin-resistant Staphylococcus aureus disease in three communities N Engl J Med 352 2005 1436 1444
10. R.C. Moellering Jr. The specter of glycopeptide resistance: current trends and future considerations Am J Med 104 1998 3S 6S
11. K. Sieradzki, R.B. Roberts, S.W. Haber, and A. Tomasz The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection N Engl J Med 340 1999 517 523
12. T.L. Smith, M.L. Pearson, K.R. Wilcox, C. Cruz, M.V. Lancaster, and B. Robinson-Dunn The glycopeptide-intermediate Staphylococcus aureus working group. Emergence of vancomycin resistance in Staphylococcus aureus N Engl J Med 340 1999 493 501
13. B.E. Murray Vancomycin-resistant enterococcal infections N Engl J Med 342 2000 710 721
14. S. Chang, D.M. Sievert, J.C. Hageman, M.L. Boulton, F.C. Tenover, and F.P. Downes For the vancomycin-resistant Staphylococcus aureus investigative team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene N Engl J Med 348 2003 1342 1347
15. F.C. Tenover, L.M. Weigel, P.C. Appelbaum, L.K. McDougal, J. Chaitram, and S. McAllister Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania Antimicrob Agents Chemother 48 2004 275 280
16. Kacica M, McDonald LC. Brief Report: vancomycin-resistant Staphylococcus aureus, New York 2004. MMWR, vol. 52, 2004. p. 322-23.
17. C.J. Whitener, S.Y. Park, F.A. Browne, L.J. Parent, K. Julian, and B. Bozdogan Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure Clin Infect Dis 38 2004 1049 1055
18. C.A. DiazGranados, S.M. Zimmer, M. Klein, and J.A. Jernigan Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis Clin Infect Dis 41 2005 327 333
19. F.C. Tenover, and L.C. Mc Donald Vancomycin-resistant staphylococci and enterococci: epidemiology and control Curr Opin Infect Dis 18 2005 300 305
20. R. Leclercq, E. Derlot, J. Duval, and P. Courvalin Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium N Engl J Med 319 1988 157 160
21. Uttley AHC, C.H. Collins, J. Naidoo, and R.C. George Vancomycin-resistant enterococci Lancet 1 1988 57 58
22. D.F. Sahm, J. Kissinger, and M.S. Gilmore In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis Antimicrob Agents Chemother 33 1989 1588 1591
23. CDC. National, nosocomial infections surveillance (NNIS) system report, data summary from January 1990 to May 1999. Am J Infect Control 1999;27:520-32.
24. W.T. Siebert, N. Moreland, and T.W. Williams Jr. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis J Infect Dis 139 1979 452 457
25. C.U. Tuazon, and H. Miller Clinical and microbiologic aspects of serious infections caused by Staphylococcus epidermidis Scand J Infect Dis 15 1983 347 360
26. A. Srinivasan, J.D. Dick, and T.M. Perl Vancomycin resistance in staphylococci Clin Micro Rev 15 2002 430 438
27. P.D. Holtom, D. Zamorano, and M.J. Patzakis Osteomyelitis attributable to vancomycin-resistant enterococci Clin Orthopaedics Rel Res 403 2002 38 44
28. CDC. Nosocomial enterococci resistant to vancomycin, United States, 1989-1993, MMWR 1993; 42:597-29.
29. R.N. Jones, S.A. Marshall, M.A. Pfaller, W.W. Wilke, R.J. Hollis, and M.E. Erwin SCOPE Hospital Study Group Diagn Microbiol Infect Dis 29 1997 95 102
30. H. Wisplinghoff, H. Seifert, S.M. Tallent, T. Bischoff, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities Pediatr Infect Dis J 22 2003 686 691
31. CDC. National Nosocomial Infection Surveillance (NNIS) System report, data summary from January 1992 through June 2004. Issued October 2004. Am J Infect Control 2004;32:470-85.
32. J.A. Karlowsky, M.E. Jones, D.C. Draghi, C. Thornsberry, D.F. Sahm, and G.A. Volturo Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002 Ann Clin Microbiol Antimicrob 3 2004 7 15
33. H. Wisplinghoff, T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317
34. Bearman GML, and R.P. Wenzel Bacteremias: a leading cause of death Arch Med Res 36 2005 646 659
35. M.M. Huycke, D.F. Sahm, and M.S. Gilmore Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future Emerg Infect Dis 4 1998 239 249
36. L.B. Rice Emergence of vancomycin-resistant enterococci Emerg Infect Dis 7 2001 183 187
37. M.E. Jones, D.C. Draghi, C. Thornsberry, J.A. Karlowsky, D.F. Sahm, and R.P. Wenzel Emerging resistance among bacterial pathogens in the intensive care unity - a European and North American surveillance study Ann Clin Microbiol Antimicrob 3 2004 14 25
38. K. Kobayashi, M. Rao, S. Keis, F.A. Rainey, Smith JMB, and G.M. Cook Enterococci with reduced susceptibility to vancomycin in New Zealand J Antimicrob Chemother 46 2000 405 410
39. L. All, M. Vera Blanch, A.M. Limansky, A.M. Viale, and R. Notario Infection outbreak due to resistant Enterococcus faecium to glycopeptides in a hospital of Rosario, Argentina Rev Fac Cien Med Univ Nac Cordoba 60 2003 55 59
40. A. El Kholy, H. Baseem, G.S. Hall, G.W. Procop, and D.L. Longworth Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals J Antimicrob Chemother 51 2003 625 630
41. M.E. Jones, J.A. Karlowsky, D.C. Draghi, C. Thornsberry, D.F. Sahm, and D. Nathwani Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy Int J Antimicrob Agents 22 2003 406 419
42. K. Lee, Y.A. Kim, Y.J. Park, H.S. Lee, M.Y. Kim, and E.C. Kim Korean Nationwide Surveillance of Antimicrobial Resistance Group. Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant Gram-negative bacilli: A KONSAR study in 2002 Yonsei Med J 45 2004 598 608
43. CDC. National nosocomial infections surveillance (NNIS) report, data summary from October 1986 to April 1996. Issued May 1996. A report from the National Nosocomial Surveillance (NNIS) system, Am J Infect Control 1996; 24, 380-88.
44. M. Bonadio, M. Meini, E. Tagliaferri, C. Gigli, and A. Vigna Enterococcal glycopeptide resistance at an Italian teaching hospital J Antimicrob Chemother 46 2000 129 131
45. H. Goossens, D. Jabes, R. Rossi, C. Lammens, G. Privitera, and P. Courvalin European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates J Antimicrob Chemother 51 2003 S5 S12
46. J. Quale, D. Landman, G. Saurina, E. Atwood, V. DiTore, and K. Patel Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci Clin Infect Dis 23 1996 1020 1025
47. Bonten MJM, and R. Williams Weinstein. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 1 2001 314 325
48. S.K. Fridkin, J.R. Edwards, J.M. Courval, H. Hill, F.C. Tenover, and R. Lawton The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units Ann Intern Med 135 2001 175 183
49. Y. Carneli, G.M. Eliopoulos, and M.H. Samore Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus Emerg Infect Dis 8 2002 802 807
50. J.G. Morris, D.K. Shay, J.N. Hebden, R.J. McCarter, B.E. Perdue, and W. Jarvis Enterococci resistant to multiple antimicrobial agents, including vancomycin Ann Int Med 123 1995 250 259
51. M.K. Hayden Insights into epidemiology and control of infection with vancomycin-resistant enterococci Clin Infect Dis 31 2000 1058 1065
52. P.E. Reynolds Structure, biochemistry and mechanism of action of glycopeptide antibiotics Eur J Clin Microbiol Infect Dis 8 1989 943 950
53. M. Arthur, P. Reynolds, and P. Courvalin Glycopeptide resistance in enterococci Trends Microbiol 4 1996 401 407
54. D. Kahne, C. Leimkuhler, W. Lu, and C. Walsh Glycopeptide and lipoglycopeptide antibiotics Chem Rev 105 2005 425 448
55. M. Arthur, C. Molinas, T.D. Bugg, G.D. Wright, C. Walsh, and P. Courvalin Evidence for in vivo incorporation of d-lactate into peptidoglycan precursors of vancomycin-resistant enterococci Antimicrob Agents Chemother 36 1992 867 869
56. S. Handwerger, M.J. Pucci, K.J. Volk, J. Liu, and M.S. Lee The cytoplasmic peptidoglycan precursor of vancomycin-resistant Enterococcus faecalis terminates in lactate J Bacteriol 174 1992 5982 5984
57. G.D. Wright, and C.T. Walsh Characterization of vanY, a DD-carboxypeptidase from vancomycin-resistant Enterococcus faecium BM4147 Antimicrob Agents Chemother 36 1992 1514 1518
58. P.E. Reynolds, and C.A. Arias Courvalin P. Gene vanXYC encodes D,D-dipeptidase (VanX) and D,D-carboxypeptidase (VanY) activities in vancomycin-resistant Enterococcus gallinarum BM4174 Mol Microbiol 34 1999 341 349
59. M. Arthur, C. Molinas, F. Depardieu, and P. Courvalin Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147 J Bacteriol 175 1993 117 127
60. M. Arthur, F. Depardieu, C. Molinas, P. Reynolds, and P. Courvalin The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin Gene 154 1995 87 92
61. J.R. McDonald, J.J. Engemann, K.S. Kaye, and D.J. Sexton Co-infection or co-colonization with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a network of community hospitals Infect Control Hosp Epidemiol 25 2004 99 104
62. R. Leclerq, S. Dutka-Malen, J. Duval, and P. Courvalin Vancomycin resistance gene vanC is specific to Enterococcus gallinarum Antimicrob Agents Chemother 36 1992 2005 2008
63. F. Navarro, and P. Courvalin Analysis of genes encoding d-alanine:d-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavens Antimicrob Agents Chemother 38 1994 1788 1793
64. B. Toye, J. Shymanski, M. Bobrowska, W. Woods, and K. Ramotar Clinical and epidemiologic significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype) J Clin Microbiol 35 1997 3166 3170
65. P.E. Reynolds, and P. Courvalin Vancomycin resistance in enterococci due to synthesis of precursors terminating in d-alanyl-d-serine Antimicrob Agents Chemother 49 2005 21 25
66. B. Perichon, P. Reynolds, and P. Courvalin VanD type glycopeptide- resistant Enterococcus faecium BM4339 Antimicrob Agents Chemother 41 1997 2016 2018
67. K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 1997 135 136
68. K. Hiramatsu, N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, and S. Hori Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin Lancet 350 1997 1670 1673
69. F.C. Tenover, M.V. Lancaster, B.C. Hill, C.D. Steward, S.A. Stocker, and G.A. Hancock Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides J Clin Microbiol 36 1998 1020 1027
70. F.C. Tenover, J.W. Biddle, and M.V. Lancaster Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus Emerg Infect Dis 7 2001 327 332
71. C. Liu, and H.F. Chambers Staphylococcus aureus with heterogeneous resistance to vancomycin epidemiology, clinical significance, and critical assessment of diagnostic methods Antimicrob Agents Chemother 47 2003 3040 3045
72. S.S. Rotun, V. McMath, D.J. Schoonmaker, P.S. Maupin, F.C. Tenover, and B.C. Hill Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia Emerg Infect Dis 5 1999 147 149
73. H. Hanaki, K. Kuwahara-Arai, S. Boyle-Vavra, R.S. Daum, H. Labischinski, and K. Hiramatsu Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50 J Antimicrob Chemother 42 1998 199 209
74. M. Kuroda, K. Kuwahara-Arai, and K. Hiramatsu Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus Mu3 and Mu50 by cDNA differential hybridization method Biochem Biophys Res Commun 269 2000 485 490
75. J.L. Koehl, A. Muthaiyan, R.K. Jayaswal, K. Ehlert, H. Labischinski, and B.J. Wilkinson Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus Antimicrob Agents Chemother 48 2004 3749 3757
76. L. Cui, J.Q. Lian, H.M. Neoh, E. Reyes, and K. Hiramatsu DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus Antimicrob Agents Chemother 49 2005 3404 3413
77. P. Vaudeaux, P. Francois, B. Berger-Bachi, and D.P. Lew In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus J Antimicrob Chemother 47 2001 163 170
78. S.M. Tallent, T. Bischoff, M. Climo, B. Ostrowsky, R.P. Wenzel, and M.B. Edmond Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections J Clin Microbiol 40 2002 2249 2250
79. G.L. Cartolano, M. Cheron, D. Benabid, M. Leneveu, and A. Boisivon Association of Hospital Bacteriologists Virologists and Hygiene Professionals. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals Clin Microbiol Infect 10 2004 448 451
80. J.H. Song, K. Hiramatsu, J.Y. Suh, K.S. Ko, T. Ito, and M. Kapi and the Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Emergence in asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin Antimicrob Agents Chemother 48 2004 4926 4928
81. J.L. Wang, S.P. Tseng, P.R. Hsueh, and K. Hiramatsu Vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus, Taiwan Emerg Infect Dis 10 2004 1702 1704
82. N. Plipat, G. Livni, H. Bertram, and R.B. Thomson Jr. Unstable vancomyin heteroresistance is common among clinical isolates of methicillin-resistant Staphylococcus aureus J Clin Microbiol 43 2005 2494 2496
83. Rybak MJ, Cha R, Cheung CM, Meka VG, Kaatz GW. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin, Diagn Microbiol Infect Dis 51:119-25.
84. G. Sakoulas, G.M. Eliopoulos, R.C. Moellering Jr., R.P. Novick, L. Venkataraman, and C. Wennersten Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187 2003 929 938
85. P.G. Charles, P.B. Ward, P.D. Johnson, B.P. Howden, and M.L. Grayson Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus Clin Infect Dis 38 2004 448 451
86. G. Sakoulas, P.A. Moisr-Broder, J. Schentag, A. Forrest, R.C.J.R. Moellering, and G.M. Eliopoulos Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 2004 2398 2402
87. M.R. Moore, F. Perdreau-Remington, and H.F. Chambers Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis Antimicrob Agents Chemother 47 2003 1262 1266
88. G. Sakoulas, G.M. Eliopoulos, R.C. Moellering Jr., C. Wennersten, L. Venataraman, and R.P. Novick Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin Antimicrob Agents Chemother 46 2002 1492 1502
89. P.A. Moise-Broder, G. Sakoulas, G.M. Eliopoulos, J.J. Schentag, A. Forrest, and R.C. Moellering Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy Clin Infect Dis 38 2004 1700 1705
90. Verdier I, Reverdy ME, Etienne J, Lina G, Bes M, Vandenesch F., Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrob Agents Chemother 48: 1024-7.
91. J. May, K. Shannon, A. King, and G. French Glycopeptide tolerance in Staphylococcus aureus J Antimicrob Chemother 42 1998 189 197
92. G. Sakoulas, G.M. Eliopoulos, V.G. Fowler Jr., R.C. Moellering Jr., R.P. Novick, and N. Lucindo Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function Antimicrob Agents Chemother 49 2005 2687 2692
93. S.S. Wong, P.L. Ho, P.C. Wuu, and K.Y. Yuen Bacteremia caused by staphylococci with inducible vancomycin heteroresistance Clin Infect Dis 29 1999 760 767
94. M.J. Schwaber, S.B. Wright, Y. Carmell, L. Venkataraman, P.C. DeGirolami, and A. Grmatikova Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia Emerg Infect Dis 9 2003 657 664
95. S.K. Fridkin, J. Hageman, L.K. McDougal, J. Mohammed, W.R. Jarvis, and T.M. Perl Vancomycin-Intermediate Staphylococcus aureus Epidemiology study group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 Clin Infect Dis 36 2003 429 439
96. J. Ariza, M. Pujol, J. Cabo, C. Pena, N. Fernandez, and J. Linares Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin Lancet 353 1999 1587 1588
97. P.B. Ward, P.D. Johnson, E.A. Grabsch, B.C. Mayall, and M.L. Grayson Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin Med J Aust 175 2001 480 483
98. B.P. Howden, P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, and P. du Cros Treatment outcomes for serious infections by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin Infect Dis 38 2004 521 528
99. B.P. Howden Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) Internal Med J 35 2005 S136 S140
100. L.M. Weigel, D.B. Clewell, S.R. Gill, N.C. Clark, L.K. McDougal, and S.E. Flannagan Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus Science 302 2003 1569 1571
101. B. Bozdogan, L. Ednie, K. Credito, K. Kosowska, and P.C. Appelbaum Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center Antimicrob Agents Chemother 48 2004 4762 4765
102. B. Bozdogan, D. Esel, C. Whitener, F.A. Browne, and P.C. Appelbaum Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center J Antimicrob Chemother 52 2003 864 868
103. R.F. Pfeltz, and B.J. Wilkinson The escalating challenge of vancomycin resistance in Staphylococcus aureus Curr Drug Targets Infect Disord 4 2004 273 294
104. F. Van Bambeke Glycopeptides in clinical development: pharmacological profile and clinical perspectives Curr Opin Pharmacol 4 2004 471 478
105. J.F. Barrett Oritavancin, Eli Lilly and Co Curr Opin Investigat Drugs 2 2001 1039 1044
106. N.E. Allen, and T.I. Nicas Mechanism of action of oritavancin and related antibiotics FEMS Microbiol Rev 26 2003 511 532
107. R.C. Mercier, and L. Hrebickova Oritavancin: a new avenue for resistant Gram-positive bacteria Expert Rev Anti-Infect Ther 3 2005 325 332
108. T.I. Nicas, D.L. Mullen, J.E. Flokowitsch, D.A. Preston, N.J. Snyder, and M.J. Zweifel Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci Antimicrob Agents Chemother 40 1996 2194 2199
109. T.I. Nicas, M.L. Zeckel, and D.K. Braun Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance Trends Microbiol 5 1997 240 249
110. M.J. Rodriguez, N.J. Snyder, M.J. Zweifel, S.C. Wilkie, D.R. Stack, and Cooper RDG Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci J Antibiotics 51 1998 560 569
111. R.N. Jones, M.S. Barrett, and M.E. Erwin In vitro activity and spectrum of LY333328, a novel glycopeptide derivative Antimicrob Agents Chemother 41 1996 488 493
112. E. Fasola, S.K. Spangler, L.M. Ednie, M.R. Jacobs, S. Bajaksouzian, and P.C. Appelbaum Comparative activities of LY 333328 a new glycopeptide, against penicillin-susceptible and -resistant pneumococci Antimicrob Agents Chemother 40 1996 2661 2663
113. S.A. Zelenitsky, J.A. Karlowsky, and G.G. Zhanel Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains Antimicrob Agents Chemother 41 1997 1407 1408
114. E. Hershberger, J.R. Aeschliman, T. Moldovan, and M.J. Rybak Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods Antimicrob Agents Chemother 43 1999 717 721
115. M.L. Zeckel, D.A. Preston, and B.S. Allen In vitro activities of LY333328 and comparative agents against nosocomial Gram-positive pathogens collected in a 1997 global surveillance study Antimicrob Agents Chemother 44 2000 1370 1374
116. A. Lefort, Saleh Mghir, L. Garry, C. Carbon, and B. Fantin Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis Antimicrob Agents Chemother 44 2000 3017 3021
117. J. Gerber, A. Smirnov, A. Wellmer, J. Ragher, J. Prange, and E. Schutz Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin Antimicrob Agents Chemother 45 2001 2169 2172
118. F. Van Bambeke, J. Saffran, Ningeot-Leclercq, and P.M. Tulkens Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation Antimicrob Agents Chemother 49 2005 1695 1700
119. M. Steiner, and F.J. Schmitz Dalbavancin Bioleach Italia/Version Curr Opin Investigat Drugs 3 2002 229 233
120. A. Malabarba, and B.P. Goldstein Origin, structure, an activity in vitro and in vivo of dalbavancin J Antimicrob Chemother 55 2005 S15 S20
121. G. Canadian, M. Abode, M. Borgonovi, G. Romano, and F. Parenti In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic J Antimicrob Chemother 44 1999 179 192
122. A. Malabarba, and S. Donadio BI 397 Drugs Future 24 1999 839 846
123. S. Lopez, C. Hackbarth, G. Romano, J. Trias, D. Jabes, and B.P. Goldstein In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide J Antimicrob Chemother 55 2005 S21 S24
124. A.C. Gales, H.S. Sader, and R.N. Jones Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centers Clin Microbiol Infect 11 2005 95 100
125. S. Mushtaq, M. Warner, A.P. Johnson, and D.M. Livermore Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods J Antimicrob Chemother 54 2004 617 620
126. G. Lin, K. Credito, L.M. Ednie, and P.C. Appelbaum Antistaphylococcal activity of dalbavancin, an experimental glycopeptide Antimicrob Agents Chemother 49 2005 770 772
127. M.B. Doerr, D. Jabes, M. Cavaleri, J. Dowell, G. Mosconi, and A. Malabarba Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide J Antimicrob Chemother 55 2005 S25 S30
128. E. Seltzer, M.B. Dorr, B.P. Goldstein, M. Perry, J.A. Dowell, and T. Henkel Dalbavancin skin and soft-tissue infection study group, once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections Clin Infect Dis 37 2003 1298 1303
129. B.P. Goldstein, E. Seltzer, R. Flamm, and D. Sahm Dalbavancin (DAL) phase 3 skin and skin structure (SSSI) studies: pathogens and microbiological efficacy. Abstracts of papers, 44th ICAAC, Washington, D.C. 2004 2004 ASM Washington, DC p. L-1577
130. J.K. Judice, and J.L. Pace Semi-synthetic glycopeptide antibacterials Biorg Med Chem Lett 13 2003 4165 4168
131. J.L. Pace, K. Krause, D. Johnston, D. Debabov, T. Wu, and L. Farrington In vitro activity of TD-6424 against Staphylococcus aureus Antimicrob Agents Chemother 47 2003 3602 3604
132. M.R. Leadbetter, S.M. Adams, B. Bazzini, P.R. Fatheree, D.E. Karr, and K.M. Krause Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424) J Antibiotics 57 2004 326 336
133. J.L. Pace, and J.K. Judice Telavancin Theravance Curr Opin Investigat Drugs 6 2005 216
134. A. King, I. Phillips, and K. Kaniga Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria J Antimicrob Chemother 53 2004 979 983
135. Goldstein EJC, D.M. Citron, V. Merriam, Y.A. Warren, K. Tyrrell, and H.T. Fernandez In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp Antimicrob Agents Chemother 48 2004 2149 2152
136. Judice JK, Shaw JP, Mu Y, Conner MW, Pace JL. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin. U.S. Patent 6,858,584.
137. G.M. Eliopoulos, C.B. Wennersten, G. Sakoulas, and R.C. Moellering Jr. In vitro bactericidal activity of telavancin (TLV) against S. aureus with relative tolerance to vancomycin (VAN). Abstracts of papers, 44th ICAAC, Washington, D.C. 2004 2004 ASM Washington, DC p. E-2011
138. S. Gander, A. Kinnaird, and R. Finch Telavancin: in vitro activity against staphylococci in a biofilm model J Antimicrob Chemother 56 2005 337 343
139. S.S. Hegde, N. Reyes, T. Wiens, N. Vanasse, R. Skinner, and J. McCullough Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria Antimicrob Agents Chemother 48 2004 3043 3050
140. A.G. Madrigal, L. Bausino, and H.F. Chambers Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 49 2005 3163 3165
141. S. Barriere, F. Genter, E. Spencer, M. Kitt, D. Hoelscher, and J. Morganroth Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects J Clin Pharmacol 44 2004 689 695
142. J.P. Shaw, J. Seroogy, K. Kaniga, D.L. Higgins, M. Kitt, and S. Barriere Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects Antimicrob Agents Chemother 49 2005 195 201
143. M.E. Stryjewski, W.D. O'Tiordan, W.K. Lau, F.D. Pien, L.M. Dunbar, and M. Vallee for the FAST Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria Clin Infect Dis 40 2005 1601 1607
144. http://www.clinicaltrials.gov
145. N.E. Allen, J.N. Hobbs Jr., and T.I. Nicas Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic Antimicrob Agents Chemother 40 1996 2356 2362
146. M. Ge, Z. Chen, H.R. Onishi, J. Kohler, L.L. Silver, and R. Kerns Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding d-Ala-d-Ala Science 284 1999 507 511
147. R. Kerns, S.D. Dong, S. Fukuzawa, J. Carbeck, J. Kohler, and L. Silver The role of hydrophobic substituents in the biological activity of glycopeptide antibiotics J Am Chem Soc 122 2000 12608 12609
148. C. Leimkuhler, L. Chen, D. Barrett, G. Panzone, B. Sun, and B. Falcone Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics J Am Chem Soc 127 2005 3250 3251
149. Debabaov DV, Pace J, Nodwell M, Trapp S, Campbell R, Karr D, Wu T, Krause K, Johnston D, Lane C, Schmidt D, Higgins D, Christensen B, Judice K, Kaniga K. TD-6424, a novel rapidly bactericidal concentration-dependent antibiotic, acts through a unique dual mode of action. Abstracts of papers, 42nd ICAAC, San Diego: 2002; C1-1809.
150. D.L. Higgins, R. Chang, D.V. Debabov, J. Leung, T. Wu, and K.M. Krause Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 49 2005 1127 1134
151. N.E. Allen, D.L. LeTourneau, J.N. Hobbs Jr., and R.C. Thompson Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies Antimicrob Agents Chemother 46 2002 2344 2348
152. D.A. Beauregard, D.H. Williams, M.N. Gwynn, and D.J.C. Knowles Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics Antimicrob Agents Chemother 39 1995 781 785
153. M.A. Cooper, and D.H. Williams Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacteria Chem Biol 6 1999 891 899
154. J.H. Griffin, M.S. Linsell, M.B. Nodwell, Q. Chen, J.L. Pace, and K.L. Quast Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimmers J Am Chem Soc 125 2003 6517 6531
155. J. Pace, K. Quast, Q. Chen, M. Linsell, K. Krause, and L. Farrington Antibacterial activity of two dimeric-Vancomycin analogues AMI 462 and AMI 905. Abstracts of Papers Proceedings of the 12th ECCMID, Milan, Italy, 24-27 April, 2002; ESCMID: Basel, Switzerland 2002 O134
156. J. Rao, L. Yan, J. Lahiri, G.M. Whitesides, R.M. Weis, and H.S. Warren Binding of a dimeric derivative of vancomycin to l-Lys-d-Ala-d-lactate in solution and at a surface Chem Biol 6 1999 353 359
157. M. Bergeret, N. Boutros, and J. Raymond In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci Int J Antimicrob Agents 23 2004 247 253
158. M. Toyokawa, S. Asari, I. Nishi, M. Horikawa, H. Tsukamoto, and A. Sunada In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus J Chemother 15 2003 31 36
159. Y.S. Kim, S. Kiem, H.J. Yun, S.I. Jung, W.S. Oh, and S.W. Kim Efficacy of
160. H.A. Albrecht, G. Beskid, K.K. Chan, J.G. Christenson, R. Cleeland, and K.H. Deitcher Cephalosporin 3′-quinolone esters with a dual mode of action J Med Chem 33 1990 77 86
161. J.L. Pace, A. Bertasso, and N.H. Georgopapadakou Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424 Antimicrob Agents Chemother 35 1991 910 915
162. Truett WL. Compounds formed from two or three antibiotics and their processes of preparation. U.S. Patent No. 6,437,119.
163. Griffin JH, Moran EJ, Christensen BG, Judice JK, Mu Y, Pace JL., Multivalent binding antibiotics. NZ Patent No. NZ505979.
164. Fatheree P, Linsell MS, Long DD, Marquess D, Moran EJ, Nodwell MB, Turner D, Aggen J., Crosslinked glycopeptide-cephalosporin antibiotics. Can. Patent Appl. 2,463,544.
165. Marquess D, Linsell MS, Turner DS, Trapp SG, Long DD, Fatheree PR, Crosslinked glycopeptide-cephalosporin antibiotics, U.S. Patent No. 6,878,686.
166. J. Freeman, S.D. Baines, D. Jabes, and M.H. Wilcox Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection J Antimicrob Chemother 56 2005 717 725
167. A. Ruzin, G. Singh, A. Severin, Y. Yang, R.G. Dushin, and A.G. Sutherland mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vanomycin-resistant Gram-positive bacteria Antimicrob Agents Chemother 48 2004 728 738
168. M.P. Singh, P.J. Petersen, W.J. Weiss, J.E. Janso, S.W. Luckman, and E.B. Lenoy Mannipeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopius LL-AC98: antibacterial and mechanistic studies Antimicrob Agents Chemother 47 2003 62 69
169. W.J. Weiss, T. Murphy, E. Lenoy, and M. Young In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models Antimicrob Agents Chemother 48 2004 1708 1712
170. D. Shin, Y. Rew, and D.L. Boger Total synthesis and structure of the ramoplanin A1 and A3 aglycons: two minor components of the ramoplanin complex Proc Natl Acad Sci USA 101 2004 11977 11979
171. E. Stegmann, D. Bischoff, C. Kittel, S. Pelzer, O. Puk, and J. Recktemwald Precursor-directed biosynthesis for the generation of novel glycopeptides Ernst Schering Res Found Workshop 51 2005 215 232
172. S. Weist, C. Kittel, D. Bischoff, B. Bister, V. Pfeifer, and G.J. Nicholson Mutasynthesis of glycopeptide antibiotics: variations of vancomycin's AB-ring amino acid 3,5-dihydroxyphenylglycine J Am Chem Soc 126 2004 5942 5943
173. B. Bister, D. Bischoff, G.J. Nicholson, S. Stockert, J. Wink, and C. Brunati Bromobalhimycin and chlorobromobalhimycins - illuminating the potential of halogenases in glycopeptide antibiotic biosyntheses Chembiochem 4 2003 658 662
174. R.G. Kruger, W. Lu, M. Oberthur, J. Tao, D. Kahne, and C.T. Walsh Tailoring of glycopeptide scaffolds by the acyltransferases from the teicoplanin and A-40,926 biosynthetic operons Chem Biol 12 2005 131 140
175. C. Walsh, C.L. Freel Myers, and H.C. Losey Antibiotic glycosyltransferases: antibiotic maturation and prospects for reprogramming J Med Chem 46 2003 3425 3436
176. T.L. Li, F. Huang, S.F. Haydock, T. Mironenko, P.F. Leadlay, and J.B. Spencer Biosynthetic gene cluster of the glycopeptide antibiotic teicoplanin: characterization of two glycosyltransferases and the key acyltransferase Chem Biol 11 2004 107 119
177. B. Sun, Z. Chen, U.S. Eggert, S.J. Shaw, J.V. LaTour, and D. Kahne Hybrid glycopeptide antibiotics J Am Chem Soc 123 2001 12722 12723
178. E.R. Baizman, A.A. Branstrom, C.B. Longley, N. Allanson, M.J. Sofia, and D. Gange Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylase Microbiology 146 2000 3129 3140
179. J. Kaplan, B.D. Korty, P.H. Axelsen, and P.J. Loll The role of sugar residues in molecular recognition by vancomycin J Med Chem 44 2001 1837 1840
180. P.J. Loll, and P.H. Axelsen The structural biology of molecular recognition by vancomycin Annu Rev Biophys Biomol Struct 29 2000 265 289
181. O. Yoshida, T. Yasukata, Y. Sumino, T. Munekage, Y. Narukawa, and Y. Nishitani Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE): doubly modified water-soluble derivatives of chloroorienticin B Bioorg Med Chem Lett 12 2002 3027 3031
182. Y. Mu, M. Nodwell, J.L. Pace, J.P. Shaw, and J.K. Judice Vancomycin disulfide derivatives as antibacterial agents Bioorg Med Chem Lett 14 2004 735 738